M.D., Ph.D., CEO, Apostle Diagnostics
Biography
Dr. Ge’s work focuses on the innovations in the public health and life science sector. Prior to Apostle, he was Director of Bioinformatics at Gilead Sciences between 2011 and 2016. Between 2008 and 2011, he was Assistant Professor at Duke University School of Medicine, where he was also a member of U.S. NIH NHGRI Special Emphasis Panel. He and colleagues discovered the IL28B genetic variants associated with clinical response to anti-HCV treatment, published in Nature in 2009.
Clinical Dx Showcase:
Apostle Diagnostics
Apostle Inc is a biotechnology company in San Jose, CA. Apostle responds to the COVID-19 pandemic with a Viral RNA Isolation System that has processed over 12 million clinical samples, as well as a CLIA lab helping international travelers.
Apostle COVID-19 RNA Extraction System
This presentation illustrates the effective detection of SARS-CoV-2 using the Apostle COVID-19 Viral RNA Isolation Automation System and qRT-PCR from over 12 million samples in clinical lab settings. A CLIA lab helping international travelers is also discussed.
Session Abstract – PMWC 2022 Silicon Valley
Track 6 - June 28 9.00 A.M.-4.45 P.M.,Track 6 - June 29 3.30 P.M.-3.45 P.M.,Track 6 - June 30 9.00 A.M.-1.15 P.M.
The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative
